Waylivra

Waylivra Uses, Dosage, Side Effects, Food Interaction and all others data.

Waylivra is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation. It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons. This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.

Waylivra was granted a conditional approval by the European Medicines Agency.

Waylivra is an antisense oligonucleotide that prevents the translation of apoC-III. It has a long duration of action as it has a half life of >2 weeks. Patients should be counselled regarding the risk of thrombocytopenia, raised LDL-C levels, renal toxicity, hepatotoxicity, and immunogenicity.

Waylivra
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Waylivra
Generic	Volanesorsen
Volanesorsen Other Names	Volanesorsen
Type
Protein binding	Volanesorsen is >98% bound to proteins in plasma. Though the exact proteins have not been identified.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Waylivra is an antisense oligonucleotide indicated to treat familial chylomicronemia.

Waylivra is conditionally approved by the EMA as an adjunct to diet in adults with familial chylomicronemia, at high risk for pancreatitis, and who have had an inadequate response to diet and triglyceride lowering therapy.

Waylivra is also used to associated treatment for these conditions: Familial Chylomicronemia

How Waylivra works

Waylivra is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation, and preventing translation of apoC-III protein. Normally, apoC-III would inhibit triglyceride metabolism and hepatic clearance of chylomicrons. Preventing translation of apoC-III allows for metabolism and breakdown of these triglycerides and chylomicrons.

Toxicity

Data regarding overdose are not readily available. However, symptoms are likely to involve injection site reactions and constitutional symptomns. Treat patients with symptomatic and supportive care.